Investment Rating - The report assigns a "Buy" rating to the company with a target price of 8.96 CNY over the next six months, up from the previous rating [1][10]. Core Insights - The company has shown significant performance recovery, with a notable increase in revenue and net profit driven by its pet business and ongoing research and development efforts [1][7]. - The revenue for the first half of 2025 reached 2.793 billion CNY, reflecting a year-on-year growth of 12.63%, while the net profit attributable to the parent company was 82 million CNY, up 30.19% year-on-year [7]. - The company is focusing on large customer development and synergistic services in the animal health sector, which is expected to enhance its profitability [7]. Financial Performance Summary - Revenue projections for 2024A, 2025E, 2026E, and 2027E are 6,017 million CNY, 6,569 million CNY, 7,190 million CNY, and 7,798 million CNY respectively, with growth rates of 11.30%, 9.17%, 9.46%, and 8.46% [2][9]. - The net profit attributable to the parent company is forecasted to be 71 million CNY in 2024A, increasing to 287 million CNY in 2025E, 351 million CNY in 2026E, and 386 million CNY in 2027E, with growth rates of -82.41%, 305.33%, 22.12%, and 9.99% respectively [2][9]. - The company’s earnings per share (EPS) are projected to be 0.07 CNY in 2024A, rising to 0.28 CNY in 2025E, 0.34 CNY in 2026E, and 0.38 CNY in 2027E [2][9]. Business Segment Performance - The pharmaceutical segment reported strong performance with sales revenue of 999 million CNY, while the biological products segment faced a decline in revenue to 450 million CNY due to increased competition [7]. - The feed segment generated revenue of 536 million CNY, indicating stable performance despite some pricing pressures [7]. - The company is actively investing in the pet health product market, with significant advancements in product development and brand promotion [7]. Research and Development - The company invested 60 million CNY in R&D in the first half of 2025, representing a year-on-year increase of 4.73%, with a research expense ratio of 2.14% [7]. - The company is focusing on developing vaccines and pharmaceuticals for pets, with several new products launched during the reporting period [7]. Valuation and Market Position - The company is valued at a PE ratio of 32 times for 2025, which is competitive compared to its peers in the animal health industry, which have an average PE of 31 times [10][11]. - The company’s market capitalization is approximately 7.577 billion CNY, with a total asset value of 8.882 billion CNY [5].

Group 1: Company Overview - Hangzhou Tianyuan Pet Products Co., Ltd. focuses on the design, development, production, and sales of pet products and food, covering various categories such as pet bedding, climbing frames, toys, electronic products, clothing, and leashes [2][3]. Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 2.764 billion, a year-on-year increase of 35.69%. Pet products generated CNY 1.530 billion (up 15.08%, 55.36% of total revenue), while pet food reached CNY 1.176 billion (up 70.80%, 42.55% of total revenue) [3]. - Revenue from overseas markets was CNY 1.332 billion (up 18.40%, 48.20% of total revenue), while domestic revenue was CNY 1.431 billion (up 57.30%, 51.80% of total revenue) [3]. Group 3: Production and Supply Chain - The company has established its own production lines for cat climbing frames and pet bedding, gradually expanding to include toys, clothing, and other pet products, focusing on high-value business segments like product design and supply chain management [3][4]. - Overseas production bases have been set up in Cambodia and Vietnam, while domestic production lines for pet clothing and electronic products have also been established [4]. Group 4: Market Strategy and Brand Development - The company aims to leverage pet food sales to drive the expansion of pet product channels, with brands like "New Food Era" and "Tianyuan It World" focusing on pet food, and five main brands for pet products [5]. - The current revenue contribution from self-owned brands is low, but the company plans to enhance channel construction and e-commerce capabilities to strengthen brand operations [5]. Group 5: Acquisition Progress - As of March 2025, the company is in the process of acquiring Taotong Technology, with ongoing audits and evaluations. The transaction requires further approval from the board and shareholders, as well as regulatory bodies [6][7].